natürliche glp 1 agonisten GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Current Insights, Advantages and Challenges

PMID: 1700785

Lim R, Beekley A, Johnson DC, Davis KA

23-25 Despite those studies showing an overall long-term benefit of tight sugar control in preventing worse retinopathy, a small percentage of subjects had a paradoxical early worsening seen in the first year

Shirley, E., & Firestein, J

Among 169,649 patients with MASLD, GLP-1 receptor agonist initiation was linked to significantly lower probability of incident cirrhosis [adjusted hazard ratio (aHR): 0.86, 95%CI: 0.80-0.93], hepatic decompensation (aHR: 0.77, 95%CI: 0.65-0.90), and hepatocellular carcinoma (HCC) (aHR: 0.79, 95%CI: 0.68-0.92) over a median follow-up of 3.5 years compared to non-users

Louis Aronne is a paid consultant and advisory board member for Eli Lilly and Company, the study sponsor and the manufacturer of orforglipron and tirzepatide.